41 / 62
Pujol J, et al. Ann Oncol 2018;29(suppl 5):Abstr 1664O
Atezolizumab
(n=43)
Chemotherapy
(n=20)
Total
(n=64)
ORR at 6 weeks, n (%)
[95%CI]
1 (2.3)
[0.0, 6.8]
2 (10)
[0.0, 23.1]
3 (4.8)
[0.0, 9.9]
DCR, n (%)
[95%CI]
9 (20.9)
[8.8, 33.1]
13 (65)
[44.1, 85.9]
22 (34.9)
[23.1, 46.7]
Progression, n (%) [95%CI]
30 (69.8)
[56.0, 83.5]
6 (30)
[9.9, 50.1]
36 (57.1)
[44.9, 69.4]
Not done/not evaluable, n
(%) [95%CI]
4 (9.3)
[0.6, 18.0]
1 (5.0)
[0.0, 14.6]
5 (7.9)
[1.3, 14.6]